Last updated: September 25, 2026
Ultram, the branded tramadol hydrochloride product originally commercialized by Ortho-McNeil, has no meaningful branded-market protection in the United States. FDA approval dates to 1995, while tramadol’s core patent protection expired decades ago. The product shifted from an originator opioid franchise to a low-cost generic market dominated by multiple manufacturers. Ultram-specific revenue is no longer separately disclosed, and the commercial value now resides mainly in generic tramadol volumes, combination products, extended-release formulations, and non-U.S. markets.
What is Ultram and how is tramadol used?
Ultram is an immediate-release oral formulation of tramadol hydrochloride, an centrally acting analgesic indicated for the management of pain severe enough to require an opioid analgesic when alternative treatments are inadequate. The product was approved by the FDA in 1995 under NDA 20-281. [1]
Tramadol has two pharmacologic components:
- Weak mu-opioid receptor activity.
- Inhibition of norepinephrine and serotonin reuptake.
The drug is metabolized in part through CYP2D6 to O-desmethyltramadol, an active metabolite. Genetic differences in CYP2D6 activity can affect analgesic response and toxicity risk. Tramadol also carries risks of respiratory depression, misuse, dependence, seizures, and serotonin syndrome. [1]
The original Ultram product competed with nonsteroidal anti-inflammatory drugs, acetaminophen, hydrocodone, oxycodone, and other opioid analgesics. Its commercial positioning historically depended on the perception that tramadol had a lower abuse potential than conventional opioids. That positioning weakened after accumulating evidence of dependence, overdose, seizures, and misuse.
When did Ultram lose patent and regulatory exclusivity?
Ultram lost commercial exclusivity long before the current generic market formed.
| Milestone |
Approximate date |
Commercial significance |
| Original tramadol compound patents |
1970s-1980s |
Core compound protection predates U.S. Ultram approval |
| FDA approval of Ultram |
1995 |
Established the U.S. branded product |
| Generic tramadol approvals |
Early 2000s |
Removed practical U.S. brand exclusivity |
| Ultram ER approval |
2005 |
Added an extended-release formulation |
| Tramadol classified as Schedule IV in the U.S. |
2014 |
Increased compliance and prescribing controls |
| Current market |
Generic-dominated |
Ultram has limited or no commercial leverage |
The core tramadol compound was discovered and patented outside the United States before Ultram entered the U.S. market. The principal economic protection therefore expired well before the product became a mature prescription franchise. The key commercial event was generic entry, not a recent patent cliff.
FDA’s Orange Book and Drugs@FDA records should be reviewed for the current status of NDA 20-281 and any historical patents or exclusivity entries. The brand’s relevant commercial protections are expired or immaterial to current generic competition. [2]
What patents protect Ultram and tramadol products?
No active U.S. patent estate appears to create a material barrier to ordinary immediate-release generic tramadol hydrochloride tablets.
Core compound patents
The underlying tramadol compound was protected by early patents associated with the original developer, Grünenthal. Those patents expired before the present U.S. generic market matured. They cannot prevent current manufacturers from selling standard tramadol products.
Immediate-release formulation patents
Immediate-release tramadol tablets are generally difficult to protect with durable formulation claims because the dosage form is conventional and the active ingredient is well established. Generic products typically rely on abbreviated new drug applications, or ANDAs, demonstrating pharmaceutical equivalence and bioequivalence rather than repeating full clinical development.
Extended-release formulations
Extended-release tramadol products can support separate intellectual-property positions based on:
- Controlled-release matrices.
- Release-rate profiles.
- Abuse-deterrent delivery systems.
- Combination products.
- Specific dosing schedules.
- Manufacturing processes.
These patents may affect individual extended-release products, but they do not restore exclusivity to immediate-release Ultram. Extended-release products also face substitution and pricing pressure from generic versions once their formulation patents and regulatory exclusivity expire.
Method-of-use patents
Tramadol’s broad pain-treatment use is old and generally unsuitable for strong, current exclusivity. Narrow method-of-use patents could cover particular patient populations, dosing regimens, or disease settings, but they would have limited effect on the broad generic market unless paired with enforceable prescribing restrictions and a commercially relevant branded product.
What is the FDA regulatory status of Ultram?
Tramadol remains an FDA-approved active ingredient, but the regulatory status of the Ultram brand is materially different from the status of generic tramadol.
The FDA approved Ultram for oral pain treatment in 1995. The agency later approved extended-release tramadol products, including Ultram ER, for once-daily pain management. [1, 3]
In 2014, the Drug Enforcement Administration placed tramadol and tramadol-containing products in Schedule IV under the Controlled Substances Act. The rule took effect on August 18, 2014. The scheduling decision increased recordkeeping, prescribing, refill, and dispensing requirements. [4]
Tramadol’s regulatory profile changed again through opioid-risk controls and broader FDA scrutiny of abuse, addiction, overdose, and respiratory-depression risks. The product is no longer commercially positioned as a low-risk alternative to other opioids.
What is the Orange Book status of Ultram?
Ultram’s Orange Book significance is historical rather than defensive.
The Orange Book is relevant for identifying:
- The reference listed drug.
- NDA and dosage-form information.
- Historical patent listings.
- Generic products approved through the ANDA pathway.
- Whether any listed patent could delay approval of a generic product.
For standard immediate-release tramadol, the market has already passed the relevant generic-entry period. A current Paragraph IV strategy against ordinary Ultram tablets would have little commercial rationale unless tied to a narrow, unexpired formulation or method-of-use claim.
A patent listing for a modified-release or combination product would not automatically block generic immediate-release tramadol. FDA patent listings are product-specific, and the scope of a listed patent depends on the dosage form, strength, labeling, and claim language. [2]
Which companies compete in the tramadol market?
The U.S. tramadol market contains a large number of generic suppliers. Manufacturers and distributors have included major generic companies such as:
- Teva Pharmaceutical Industries.
- Endo Pharmaceuticals and Par Pharmaceutical.
- Hikma Pharmaceuticals.
- Amneal Pharmaceuticals.
- Rising Pharmaceuticals.
- Zydus Pharmaceuticals.
- Rhodes Pharmaceuticals.
- ANI Pharmaceuticals.
- Solco Healthcare.
- Major wholesaler and pharmacy-label suppliers.
The active competitor set changes because ANDA holders enter, exit, transfer products, or discontinue specific strengths. Competition is strongest for common immediate-release strengths, including 50 mg tablets.
The commercial basis of competition is usually:
- Contract pricing.
- Manufacturing reliability.
- Supply continuity.
- Wholesaler access.
- Pharmacy purchasing agreements.
- Product quality and regulatory history.
- Ability to maintain multiple dosage strengths.
Brand recognition for Ultram has limited impact because pharmacists and payers generally favor lower-cost generic substitution.
How does tramadol compare with competing opioid analgesics?
| Product |
Market position |
Regulatory status |
Generic pressure |
Key commercial issue |
| Ultram/tramadol IR |
Mature analgesic |
Schedule IV |
Very high |
Low price and broad supplier base |
| Tramadol ER |
Modified-release analgesic |
Schedule IV |
High, depending on product |
Formulation and bioequivalence barriers |
| Hydrocodone/acetaminophen |
Higher-potency opioid combination |
Schedule II |
High |
Opioid controls and acetaminophen limits |
| Oxycodone products |
Higher-potency opioid |
Schedule II |
High |
Abuse scrutiny and formulary restrictions |
| Codeine products |
Older opioid analgesic |
Schedule II or III depending on formulation |
High |
Variable efficacy and safety |
| NSAIDs |
Non-opioid analgesics |
Noncontrolled |
High |
Gastrointestinal, renal, and cardiovascular risks |
Tramadol’s commercial niche is between non-opioid analgesics and stronger Schedule II opioids. Its lower perceived potency supports use in moderate pain, but its Schedule IV classification and safety warnings reduce differentiation.
What is the financial trajectory of Ultram?
Ultram’s financial trajectory has four phases.
Originator growth
After FDA approval in 1995, Ultram benefited from physician familiarity, branded promotion, and a market position between NSAIDs and stronger opioids. Product economics were strongest while the brand controlled distribution and generic substitution was limited.
Generic erosion
Generic entry caused rapid price compression and loss of branded prescription share. In mature oral solid-dose markets, multiple ANDA holders typically force prices down through pharmacy benefit manager contracting and wholesaler competition.
Portfolio migration
Commercial value moved away from the Ultram name and toward:
- Generic tramadol.
- Tramadol ER.
- Tramadol/acetaminophen combinations.
- International products.
- Institutional and hospital supply contracts.
Combination products such as tramadol/acetaminophen are commercially distinct but remain vulnerable to generic competition.
Mature generic phase
Today, Ultram is not a material standalone growth asset for the original innovator. Johnson & Johnson’s public reporting does not identify Ultram as a separate revenue line, and generic manufacturers generally do not report tramadol revenue as a distinct major product franchise. [5]
The market is therefore best analyzed through prescription volume, average selling price, manufacturer participation, and supply conditions rather than brand revenue. Brand-level revenue estimates published by commercial market-research providers may include generic tramadol, extended-release products, combination products, or non-U.S. sales and should not be treated as Ultram-only revenue.
What revenue exposure remains for manufacturers?
Revenue exposure is concentrated in generic-volume economics rather than patent rents.
| Revenue source |
Current importance |
Margin profile |
| Branded Ultram immediate-release tablets |
Low |
Limited or obsolete |
| Generic immediate-release tramadol |
High in volume, low per-unit value |
Low to moderate |
| Extended-release tramadol |
Product-specific |
Higher if supply is constrained |
| Tramadol/acetaminophen combinations |
Moderate |
Competitive |
| Hospital and institutional contracts |
Moderate |
Price-sensitive |
| International tramadol markets |
Material in selected countries |
Depends on regulation and local competition |
Supply interruptions, controlled-substance quotas, manufacturing inspections, and API availability can temporarily improve pricing. These effects are usually operational and short-lived, not evidence of durable patent power.
Are there Paragraph IV challenges involving Ultram?
Paragraph IV litigation was commercially relevant when generic applicants first sought approval for protected products. For standard immediate-release Ultram, that period has passed.
A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. It can trigger litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman framework. [6] Current litigation risk for ordinary tramadol tablets is low because the core patents are expired and the market has numerous generic approvals.
Residual Paragraph IV risk could arise for a specific:
- Extended-release formulation.
- Combination product.
- Abuse-deterrent design.
- Narrow method-of-use label.
- Manufacturing process.
That risk would apply to the particular product and patent claims, not to tramadol as a molecule.
What generic launch scenarios exist for Ultram?
The likely commercial scenarios are:
- Continued low-price generic supply for immediate-release tablets.
- Periodic supplier exits caused by low margins or compliance costs.
- Temporary price increases after manufacturing or API disruptions.
- Continued substitution from brand Ultram to generic tramadol.
- Incremental competition in extended-release and combination products.
- Further demand pressure from opioid-prescribing controls and non-opioid treatment guidelines.
A new generic entrant would face limited regulatory risk for ordinary immediate-release tablets but substantial pricing risk. The principal barrier is commercial scale, not intellectual property.
How strong is the Ultram patent estate?
The patent estate is weak for current commercial purposes.
| Patent factor |
Assessment |
| Core compound protection |
Expired |
| Immediate-release formulation protection |
No material current barrier |
| Extended-release protection |
Product-specific and potentially narrower |
| Method-of-use protection |
Limited practical scope |
| Orange Book leverage |
Historical |
| Paragraph IV exposure |
Low for ordinary IR tablets |
| Biosimilar risk |
Not applicable |
| Generic substitution risk |
Very high |
| Manufacturing barriers |
Moderate, mainly regulatory and supply-chain based |
Biosimilar analysis does not apply because tramadol is a small-molecule drug, not a biologic. The relevant competitive pathway is the ANDA generic pathway.
What litigation, licensing deals, and settlement agreements affect Ultram?
No current high-value licensing or settlement structure appears to support a defensible Ultram franchise. The market’s major legal events were associated with generic entry, product liability, opioid-control regulation, and formulation-specific disputes rather than an active brand-protection strategy.
Any historical settlement involving a generic applicant would have limited present commercial importance unless it affected a still-protected extended-release or combination product. Product-liability litigation has broader implications for opioid manufacturers but does not restore exclusivity or materially improve Ultram economics.
Key Takeaways
- Ultram is the original U.S. brand for tramadol hydrochloride.
- FDA approval occurred in 1995 under NDA 20-281.
- Core compound and immediate-release commercial protections expired long ago.
- Generic tramadol dominates the U.S. market.
- Ultram-specific revenue is not separately reported by the original manufacturer.
- The current market is driven by volume, pricing, supply reliability, and controlled-substance compliance.
- Extended-release and combination formulations may have product-specific patent issues.
- Paragraph IV risk is low for ordinary immediate-release tramadol.
- Biosimilar risk does not apply.
- The principal threat is generic price erosion, not a new patent cliff.
Frequently Asked Questions
Is Ultram still sold in the United States?
Generic tramadol remains widely available. The commercial status of the original Ultram brand is limited compared with the generic market.
Is tramadol stronger than hydrocodone?
Tramadol is generally considered less potent than hydrocodone, but individual response varies. Tramadol still carries opioid, seizure, serotonin-syndrome, dependence, and respiratory-depression risks.
Does Ultram have patent protection in 2025?
No material patent protection appears to block ordinary immediate-release generic tramadol. Specific extended-release or combination products may have separate historical or product-specific patent issues.
Why did tramadol become a Schedule IV controlled substance?
The DEA cited abuse, dependence, and public-health risks when it placed tramadol in Schedule IV effective August 18, 2014. [4]
Is Ultram a biologic or biosimilar product?
No. Ultram contains the small-molecule active ingredient tramadol hydrochloride. Generic tramadol is approved through the ANDA pathway, not the biosimilar pathway.
References
- U.S. Food and Drug Administration. (2010). Ultram prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Food and Drug Administration. (2005). Ultram ER prescribing information. FDA.
- Drug Enforcement Administration. (2014). Placement of tramadol into Schedule IV. 79 Fed. Reg. 37623.
- Johnson & Johnson. (2024). Annual report 2023.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
